Clinical Trial

A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1, single-arm, single-center, open-label, prospective, dose-escalation, and cohort expansion study to assess the safety, tolerability, pharmacokinetic (PK), and preliminary efficacy of WSK-IM02 administered as a single agent to patients with platinum-resistant recurrent ovarian cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-04.
Trial Details
NCT Number NCT07462468
Lead Sponsor WestVac Biopharma Co., Ltd.
Conditions Platinum-resistant Recurrent Ovarian Cancer (PROC)
Enrollment 36 participants
Start Date 2026-03-10
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-13